Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies

Woelfl, S.; Bogner, Savannah J.; Huber, Hans E.; Salaheddin-Nassr, S.; Hatzl, Margit; Decristoforo, Clemens; Virgolini, Irene; Gabriel, Michael

doi:10.3413/nukmed-0646-14-02

Cited by 16 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we have demonstrated that SSTR2A and SSTR5 are expressed in various degrees in a portion (66.0% and 37.5%, respectively) of MTCs. This is in concordance with other studies . SSTR2A and 5 staining was always combined membranous and cytoplasmic.…”

Section: Discussionsupporting

confidence: 93%

Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis

Herac

Niederle

Raderer

et al. 2016

APMIS

View full text Add to dashboard Cite

Medullary carcinoma (MTC) is an aggressive tumour that derives from the thyroid parafollicular calcitonin-secreting cells (C cells). Lymph node metastasis may occur early in disease pathogenesis and is one of the most important negative prognostic parameters. Surgery is the only curative therapy while chemotherapeutic options are limited. Neuroendocrine differentiated C cells may express somatostatin receptors (SSTR), which have a wide range of biological actions including inhibitory effects on cell survival and angiogenesis and antiproliferative effects on cancer cell lines. Moreover, they are a potential target for various somatostatin analogues. Aim of this study was to analyse the protein expression of SSTR2A and 5 in MTCs with or without the presence of lymph node metastases in correlation with various clinicopathological parameters. This retrospective immunohistochemical analysis included 97 patients with medullary thyroid carcinomas. Protein expression was detected by immunohistochemistry for somatostatin receptors 2A and 5. Various clinicopathological parameters, such as Ki-67 proliferation index or presence of desmoplasia, were included for statistical analysis. SSTR2A protein expression significantly correlated with the presence of lymph node metastases (p = 0.009), locally advanced MTCs staged according to the TNM (p < 0.001) and degree of desmoplasia (p = 0.029). Although SSTR5 protein expression significantly correlated with advanced stages of MTCs (p = 0.023) and degree of desmoplasia (p = 0.020), no correlation was found with the presence of lymph node metastases. Our results provide additional information concerning the aggressiveness of MTCs and reveal that a high SSTR2A and SSTR5 expression might be a poor prognostic feature.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis

Herac

Niederle

Raderer

et al. 2016

APMIS

View full text Add to dashboard Cite

show abstract

“…SST 2 was present in 43%–66% of medullary as well as in papillary and follicular thyroid carcinomas ( Papotti et al, 2001 ; Druckenthaner et al, 2007 ; Mussig et al, 2012; Pazaitou-Panayiotou et al, 2012 ; Atkinson et al, 2013 ; Woelfl et al, 2014 ; Herac et al, 2016 ). SST 2 was also detected in a high percentage (>70%) of pheochromocytomas and paragangliomas ( Fischer et al, 2008 ; Lupp et al, 2011 ; Saveanu et al, 2011 ; Elston et al, 2015 ) as well as in 33% of both functioning and nonfunctioning adrenocortical adenomas ( Unger et al, 2008 ).…”

Section: Somatostatin Receptormentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

et al. 2018

View full text Add to dashboard Cite

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.

show abstract

“…SSTRs are one class of receptors that could be targeted using NPs. These receptors are found either exposed on the surface of the cell or within the cell [9][10][11]. These cells are target cells for that ligand while cells which do not have such a receptor cannot be influenced directly by that ligand [12].…”

Section: Introductionmentioning

confidence: 99%

Targeting of Somatostatin Receptors Using Fluorescent Nanoparticles

Abdellatif¹

2018

J Nanomed Nanotechnol

View full text Add to dashboard Cite

show abstract

Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies

Cited by 16 publications

References 28 publications

Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis

Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

Targeting of Somatostatin Receptors Using Fluorescent Nanoparticles

Contact Info

Product

Resources

About